These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2408209)

  • 1. Agonist potency and apparent affinity: interpretation using classical and steady-state ternary-complex models.
    Mackay D
    Trends Pharmacol Sci; 1990 Jan; 11(1):17-22. PubMed ID: 2408209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpretation of relative potencies, relative efficacies and apparent affinity constants of agonist drugs estimated from concentration-response curves.
    Mackay D
    J Theor Biol; 1990 Feb; 142(3):415-27. PubMed ID: 2338830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative version of steady-state ternary-complex model. Agonist potency, affinity and efficacy.
    Mackay D
    Trends Pharmacol Sci; 1990 Mar; 11(3):102-3. PubMed ID: 2104460
    [No Abstract]   [Full Text] [Related]  

  • 4. Estimation of agonist affinity and efficacy by direct, operational model-fitting.
    Leff P; Prentice DJ; Giles H; Martin GR; Wood J
    J Pharmacol Methods; 1990 May; 23(3):225-37. PubMed ID: 2329803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of receptor interactions of agonists and antagonists.
    Kenakin T
    Curr Protoc Pharmacol; 2008 Sep; Chapter 4():Unit 4.1. PubMed ID: 22294222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The two-modes-of-binding model for partial agonism and the design of partial agonists.
    Topiol S; Osman R; Schulman JM
    Eur J Pharmacol; 1984 Jun; 101(3-4):249-52. PubMed ID: 6468498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do pharmacological methods for the quantification of agonists work when the ternary complex mechanism operates?
    Leff P; Harper D
    J Theor Biol; 1989 Oct; 140(3):381-97. PubMed ID: 2515395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theoretical effects of single and multiple transducer receptor coupling proteins on estimates of the relative potency of agonists.
    Kenakin TP; Morgan PH
    Mol Pharmacol; 1989 Feb; 35(2):214-22. PubMed ID: 2537459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction of human haemoglobin with allosteric effectors as a model for drug-receptor interactions.
    Goodford PJ; St-Louis J; Wootton R
    Br J Pharmacol; 1980 Apr; 68(4):741-8. PubMed ID: 7378645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs and receptors. An overview of the current state of knowledge.
    Kenakin T
    Drugs; 1990 Nov; 40(5):666-87. PubMed ID: 2292230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desensitization, two-state receptors and pharmacological parameters.
    Gero A
    J Theor Biol; 1983 Jul; 103(1):137-61. PubMed ID: 6621065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Principles of pharmacodynamics and their applications in veterinary pharmacology.
    Lees P; Cunningham FM; Elliott J
    J Vet Pharmacol Ther; 2004 Dec; 27(6):397-414. PubMed ID: 15601436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Errors in agonist affinity estimation: do they and should they occur in isolated tissue experiments?
    Leff P; Dougall IG; Harper DH; Dainty IA
    Trends Pharmacol Sci; 1990 Feb; 11(2):64-7. PubMed ID: 2180161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy in drug receptor theory: outdated concept or under-valued tool?
    Kenakin T
    Trends Pharmacol Sci; 1999 Oct; 20(10):400-5. PubMed ID: 10498953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.
    Fitzgerald LW; Conklin DS; Krause CM; Marshall AP; Patterson JP; Tran DP; Iyer G; Kostich WA; Largent BL; Hartig PR
    J Neurochem; 1999 May; 72(5):2127-34. PubMed ID: 10217294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo potency revisited - Keep the target in sight.
    Gabrielsson J; Peletier LA; Hjorth S
    Pharmacol Ther; 2018 Apr; 184():177-188. PubMed ID: 29024741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spare receptors, partial agonists, and ternary complex model of drug action.
    Homer LD; Nielsen TB
    Am J Physiol; 1987 Jul; 253(1 Pt 1):E114-21. PubMed ID: 2886052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulus amplification, efficacy, and the operational model. Part II--ternary complex occupancy mechanisms.
    Trzeciakowski JP
    J Theor Biol; 1999 Jun; 198(3):347-74. PubMed ID: 10366491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An alternative model for non-competitive antagonism.
    Brandt HD; Offermeier J
    Arch Int Pharmacodyn Ther; 1977 Feb; 225(2):180-95. PubMed ID: 849068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of adenylate cyclase is mediated by the high affinity conformation of the alpha 2-adrenergic receptor.
    Thomsen WJ; Jacquez JA; Neubig RR
    Mol Pharmacol; 1988 Dec; 34(6):814-22. PubMed ID: 2904647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.